Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 158 Jul 28 – Oct 25, 2026
- Disclosed funding
- $6B 122 disclosed amounts
- Median round
- $24M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| M MicrobioticaCompany profile Microbiotica develops oral medicines made from selected live bacteria for inflammatory diseases and cancer treatment. Microbiotica develops oral medicines made from selected live bacteria for inflammatory diseases and cancer treatment. | £36M | Series C first closeSeries C+ | Biotech | United Kingdom | Investors | |
| EB Estuary BiotherapeuticsCompany profile Estuary Biotherapeutics develops locally delivered gene therapies for patients with inherited polycystic kidney disease. Estuary Biotherapeutics develops locally delivered gene therapies for patients with inherited polycystic kidney disease. | $93M | Series A | Biotech | United States | Investors | |
| A AdipoSeedsCompany profile AdipoSeeds develops platelet-based regenerative medicine and platelet-processing technology. AdipoSeeds develops platelet-based regenerative medicine and platelet-processing technology. | Undisclosed | Strategic investmentUndisclosed | Biotech | Japan | Investors | |
| OT OMass TherapeuticsCompany profile OMass Therapeutics develops small-molecule medicines for endocrine and immune diseases using a platform that measures drug targets in their biological surroundings. OMass Therapeutics develops small-molecule medicines for endocrine and immune diseases using a platform that measures drug targets in their biological surroundings. | $310M | Series CSeries C+ | Biotech | United Kingdom | Investors | |
| AP Acta PharmaceuticalsCompany profile Develops investigational medicines for early intervention in Alzheimer’s disease. Develops investigational medicines for early intervention in Alzheimer’s disease. | $24M | Total seed financingSeed | Biotech | United States | Investors Undisclosed | |
| SB Silvia BioCompany profile Cell profiling and media additives for more predictable biopharmaceutical manufacturing. Cell profiling and media additives for more predictable biopharmaceutical manufacturing. | £3M | Seed | Biotech | United Kingdom | Investors | |
| H Enzyme-based catalysts for industrial chemical manufacturing. | $8M | Series A first closeSeries A | Biotech | United Kingdom | Investors | |
| s Quantitative biomarkers for diseases driven by protein aggregation. | €12M | Mixed financingUndisclosed | Biotech | Germany | Investors | |
| M MolagriCompany profile Molagri develops targeted crop-protection products for growers facing pesticide resistance. Molagri develops targeted crop-protection products for growers facing pesticide resistance. | Undisclosed | Seed | Biotech, Agritech | Canada | Investors | |
| O Climate-resilient cereal genetics for commercial seed programs. | €5M | Seed | Biotech, Agritech | Sweden | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jul 28, 2026
- 1Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
10rounds0led - 2RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
9rounds3led - 3Y Combinator (YC)
Molagri, Sensible Biotechnologies, WonderTx
6rounds0led - 4Catalio Capital Management
BigHat Biosciences, Basecamp Research, Enveda
6rounds2led - 5Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
5rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.